Designing resilience into global drug launches

At Ensera, we see this shift clearly. Customers are asking how fast they can enter additional markets, and whether their launch model will hold up when demand shifts, requirements evolve, or sequencing changes.  

I spoke to John Ward (VP Pharma EMEA at Ensera) to explore how the changing mindset around resilience planning is helping a new breed of pharma programs prepare for success. 

Why traditional launch models are under strain

Historically, global launches were phased. A core market came first, followed by additional territories once demand, supply, and regulatory expectations were clear. Manufacturing and packaging were typically optimized around that initial step. 

That approach is harder to sustain in a world where development timelines are compressed, regulatory expectations can evolve mid-program, and commercial teams push for broader launch readiness earlier. At the same time, programs carry more complexity: smaller patient populations, multiple presentations (e.g. vial, prefilled syringe, autoinjector), and region-specific packaging and labeling requirements. 

When those pressures meet tightly optimized models, fragility emerges. A single constrained site becomes a bottleneck. Small changes upstream trigger downstream disruption. Assembly, packaging, labeling, and artwork management, often assumed to be execution steps, become the points where timelines slip and cost escalates. 

Manufacturing strategy sets the foundation 

The credibility of a global launch strategy is shaped much earlier in development than many teams expect. Decisions around fill location, downstream assembly, packaging structure, and process validation are often made to support a single scenario. Once locked, they are difficult and expensive to change. So, it makes sense to build this in from the outset. 

Common fragility points include: 

Single-site dependency
A model built around one site may support initial regulatory approval, but it can slow later expansion. Tech transfer and revalidation timelines become critical constraints when additional markets need to be brought forward. 

Packaging operations built for one region
Production lines designed around a single configuration can struggle with multi-market requirements, including language variants, pack sizes, leaflets, and serialization. Each additional SKU increases changeovers, line clearance complexity, and the risk of error. 

Equipment selected for one presentation
Tools and processes optimized for one format can limit the introduction of others. Adding a new presentation may require revalidation, process redesign, and new inspection and packaging steps. 

These challenges are amplified in small to mid-volume programs, where short runs and frequent changeovers are common. If the model assumes one pathway, expansion becomes difficult. If it accounts for multiple markets early, adaptation is far more manageable. 

Redundancy and flexibility are not opposites 

Duplicating rigid systems across sites adds validation burden and operational overhead while still limiting the ability to adapt. A more effective approach combines redundancy with flexibility: 

• Equipment that supports multiple formats and pack configurations
• Harmonized processes that can be deployed across locations
• Aligned Quality systems that reduce friction when work shifts
• Defined site roles that can evolve as program needs change 

This is what makes redundancy usable. It supports continuity without locking programs into inflexible structures.

The role of integrated partnerships 

As launch strategies evolve, so do expectations of the role partners should play. Our pharmaceutical customers increasingly look for continuity across development, launch, and expansion, rather than a series of handoffs between sites or providers. 

Resilience as a launch advantage

The most successful global launches are not those that avoid disruption entirely. They are the ones that continue to move when disruption occurs. 

In a market defined by uncertainty, resilience is a competitive advantage. Companies that design it into their launch strategies early are better positioned to adapt, scale, and extend value across regions – and do so more quickly. 

If your launch model is built around a single market or configuration, it may be more brittle than it appears. Ensera helps teams design downstream operating models across assembly, packaging, and labeling that support multi-market expansion with fewer delays and less rework when plans change. 

Are you planning a global launch for a drug-device combination product?

Get in touch to learn how Ensera’s services add resilience to your plan.